36.97
price up icon1.68%   0.61
after-market アフターアワーズ: 36.97
loading
前日終値:
$36.36
開ける:
$37.04
24時間の取引高:
992.46K
Relative Volume:
0.92
時価総額:
$2.20B
収益:
$66.05M
当期純損益:
$-422.60M
株価収益率:
-5.0986
EPS:
-7.251
ネットキャッシュフロー:
$-384.73M
1週間 パフォーマンス:
-7.71%
1か月 パフォーマンス:
-2.45%
6か月 パフォーマンス:
+28.95%
1年 パフォーマンス:
-7.58%
1日の値動き範囲:
Value
$36.23
$38.74
1週間の範囲:
Value
$35.09
$39.37
52週間の値動き範囲:
Value
$22.24
$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1074)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
540
Name
Twitter
@AgiosPharma
Name
次回の収益日
2026-07-30
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AGIO icon
AGIO
Agios Pharmaceuticals Inc
36.97 2.16B 66.05M -422.60M -384.73M -7.251
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 繰り返されました H.C. Wainwright Buy
2025-11-24 開始されました Truist Buy
2025-11-20 アップグレード Leerink Partners Market Perform → Outperform
2025-11-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
07:03 AM

Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

07:03 AM
pulisher
03:01 AM

Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey

03:01 AM
pulisher
02:08 AM

Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

02:08 AM
pulisher
Jul 26, 2026

Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

AGIO|Agios Pharmaceuticals Inc|Price:36.360|Chg%:+0.080 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO - TradingView

Jul 25, 2026
pulisher
Jul 24, 2026

Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Jul 24, 2026
pulisher
Jul 24, 2026

Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail

Jul 24, 2026
pulisher
Jul 23, 2026

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Jul 23, 2026
pulisher
Jul 22, 2026

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm

Jul 22, 2026
pulisher
Jul 22, 2026

AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - TradingView

Jul 22, 2026
pulisher
Jul 22, 2026

H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com - Investing.com South Africa

Jul 22, 2026
pulisher
Jul 22, 2026

H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com

Jul 22, 2026
pulisher
Jul 22, 2026

Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus

Jul 22, 2026
pulisher
Jul 22, 2026

Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus

Jul 22, 2026
pulisher
Jul 22, 2026

Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus

Jul 22, 2026
pulisher
Jul 21, 2026

AGIO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Jul 21, 2026
pulisher
Jul 21, 2026

Agios scraps sickle cell treatment after trial shows limited benefit - Reuters

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharmaceuticals stock falls on trial update - Investing.com

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint - MedCity News

Jul 21, 2026
pulisher
Jul 21, 2026

Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ) - Seeking Alpha

Jul 21, 2026
pulisher
Jul 21, 2026

Agios scraps sickle cell drug - BioPharma Dive

Jul 21, 2026
pulisher
Jul 21, 2026

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Investor's Business Daily

Jul 21, 2026
pulisher
Jul 21, 2026

Trial miss for Agios Pharma’s tebapivat in sickle cell disease - The Pharma Letter

Jul 21, 2026
pulisher
Jul 21, 2026

Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset - BioSpace

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit - insights.citeline.com

Jul 21, 2026
pulisher
Jul 21, 2026

Why Is AGIO Stock Falling Today? - TradingView

Jul 21, 2026
pulisher
Jul 21, 2026

Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Yahoo Finance

Jul 21, 2026
pulisher
Jul 21, 2026

Agios halts tebapivat development in sickle cell disease - Investing.com

Jul 21, 2026
pulisher
Jul 21, 2026

Agios halts tebapivat development in sickle cell disease By Investing.com - Investing.com Nigeria

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharmaceuticals stock falls on trial update By Investing.com - Investing.com Canada

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharmaceuticals Reports Phase 2 Tebapivat Sickle Cell Disease Results, Discontinues Development of the Candidate - Quiver Quantitative

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharmaceuticals Shares Down 12.6% Prema - Moomoo

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - The Manila Times

Jul 21, 2026
pulisher
Jul 21, 2026

Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance - Stock Titan

Jul 21, 2026
pulisher
Jul 21, 2026

Agios Pharmaceuticals (AGIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Jul 21, 2026
pulisher
Jul 19, 2026

The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell - simplywall.st

Jul 19, 2026
pulisher
Jul 18, 2026

Agios gains FDA priority review for Pyrukynd label expansion - MSN

Jul 18, 2026
pulisher
Jul 16, 2026

The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily

Jul 16, 2026
pulisher
Jul 16, 2026

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued? - Sahm

Jul 16, 2026
pulisher
Jul 15, 2026

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com

Jul 15, 2026
pulisher
Jul 14, 2026

H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo

Jul 14, 2026
pulisher
Jul 13, 2026

AGIO 260717 45.00P (AGIO260717P45000) Latest Announcements - Moomoo

Jul 13, 2026
pulisher
Jul 10, 2026

Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan

Jul 10, 2026
pulisher
Jul 10, 2026

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com

Jul 10, 2026
pulisher
Jul 09, 2026

Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance

Jul 09, 2026
pulisher
Jul 09, 2026

Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Yahoo Finance

Jul 09, 2026
pulisher
Jul 08, 2026

AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - The Globe and Mail

Jul 08, 2026
pulisher
Jul 08, 2026

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance

Jul 08, 2026

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):